Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 7Gastrointestinal Stromal Tumors 5Urologic Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Carcinoma 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thymoma 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

durvalumab 3selpercatinib 2palbociclib 2Gonadotropin-Releasing Hormone 2Cisplatin 2Anastrozole 2AZD9833 2ribociclib 1pembrolizumab 1gallium 68 PSMA-11 1ceralasertib 1camrelizumab 1anlotinib 1abemaciclib 1Taxes 1Surgical Procedures, Operative 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Pemetrexed 1Paclitaxel 1Nimorazole 1Letrozole 1Immunotherapy 1Fulvestrant 1CP protocol 1Aspirin 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms by Site × Sunitinib × Clear all
NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

AstraZeneca

Phase 3 Active not recruiting
60 enrolled 15 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡